Latest Japan News

Zeotech pushed forward its AusPozz™ metakaolin commercialisation with extended and new MOUs, progressed key Toondoon project approvals amid rising contractor costs, and launched live methane control trials.

Ardea Resources is progressing its Kalgoorlie Nickel Project’s Definitive Feasibility Study with strong financial and strategic support from a Japanese Consortium and government export banks, aiming to secure a major nickel-cobalt supply chain.

Sovereign Metals' March 2026 update reveals a robust DFS for its Kasiya Rutile-Graphite Project, a substantial resource upgrade, strategic offtake MOUs, and a high-value heavy rare earth by-product discovery.

Icetana AI reported a 51% year-on-year jump in annual recurring revenue to $2.6 million but faced a $1.2 million net operating cash outflow in Q3 FY26, prompting plans for a capital raise amid expected cash flow improvements.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

Atomos has finalized its acquisition of Flanders Scientific for $2.35 million cash plus shares, funded by a new $10 million finance facility from Commonwealth Bank. The deal broadens Atomos’ professional video monitoring reach and is expected to add $1 million EBITDA before growth.

Tivan Limited has added Major Michael Stone (Retd) to its Technical Advisory Group, leveraging his 25 years of Timor-Leste expertise to boost local engagement and strategic guidance for its copper-gold projects. This move bolsters Tivan’s in-country capabilities as it advances its Turiscai, Baucau, and Ossu exploration portfolio.

Diatreme Resources reported a $745,000 net loss for FY 2025 but strengthened its financial footing through asset sales and an IPO stake. The company’s Northern Silica Project and Cyclone Zircon Project showed significant technical progress, while a major Cape Flattery asset sale aims to streamline operations and unlock funding.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

De.mem Limited has extended its growth streak with record quarterly cash receipts of approximately $10.4 million, a 31% increase year-on-year, alongside positive operating cash flow of $504,000 for the March 2026 quarter.

Delta Lithium’s March quarter report highlights robust high-grade lithium drilling at Mt Ida, successful production of battery-grade lithium and rubidium carbonates, and ongoing exploration progress at Yinnetharra, supported by a strong $52 million cash position.

Iron Road Ltd faces headwinds in securing partners for its Central Eyre Iron Project amid market and energy volatility, delays drilling at Mulgathing due to flooding, but reports promising heavy mineral sands results and evolving land option dynamics at Cape Hardy.